VectorY Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
VectorY Therapeutics - overview
Established
2020
Location
Amsterdam, -, Netherlands
Primary Industry
Biotechnology
About
Founded in 2020 and based in Amsterdam, Netherlands, VectorY operates as a biotechnology company that focuses on therapeutic solutions. In November 2023, VectorY Therapeutics raised EUR 129 million in series A funding co-led by EQT Life Sciences and Forbion, with participation from BioGeneration Ventures, Insight Partners, MRL Ventures Fund, and SUNU Ventures. VectorY develops gene therapy for muscular and neurodegenerative disorders. The firm develops vectorized antibodies for CNS and somatic disorders.
VectorY plans to use its seed funding to establish pre-clinical proof of concept for vectorized antibodies in target indications of ALS and Alzheimer’s, expand its team, and establish manufacturing capabilities, including the GMP facility in the Netherlands.
Current Investors
Forbion, BioGeneration Ventures, Eli Lilly & Company
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.vectorytx.com/
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
VectorY Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (6,497,000) | - | - | - |
| Operating Income (USD) | (7,009,000) | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (7,279,000) | - | - | - |
| % Net Margin | - | - | - | - |
VectorY Therapeutics - employee data
VectorY Therapeutics - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.